ARNA Financial Facts

Net loss per share allocable to common stockholders, diluted: 0.03
Other: 274K
See Full Income Statement

Current portion of deferred revenues: 32.46M
Deferred revenues, less current portion: 96.67M
See Full Balance Sheet

Arena Pharmaceuticals, Inc. (ARNA) Earnings

  |   Expand Research on ARNA
Next EPS Date 11/7/14 *Est. EPS Growth Rate -83.3% *Last Qtr.
Average EPS % Beat Rate +35.2% Revenue Growth Rate -81.4% *Last Qtr.
Average % Move 1-Wk after EPS +3.3% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/1/14 Q214 $0.03-$0.11 +$0.14$12.8M$9.81M N/A Details
5/12/14 Q114 -$0.12-$0.10 -$0.02$6.8M$7.98M N/A Details
2/27/14 Q413 -$0.11-$0.11 $0.00$6.2M$7M N/A Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$3.6M$5.3M N/A Details
8/1/13 Q213 $0.18$0.15 +$0.03$68.9M$57.3M N/A Details
5/2/13 Q113 $0.09$0.11 -$0.02N/A$50.36M N/A Details
3/4/13 Q412 -$0.10-$0.03 -$0.07$1.94M$21.94M N/A Details
11/6/12 Q312 -$0.07-$0.09 +$0.02$1.49M$3.51M N/A Details